Skip to content
DataLookout
Menu

MILD-EFFECTNCT07944261

Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-1
Timeframe: 90 ± 7 days after randomization

Secondary (16)

Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-2
Distribution of Modified Rankin Scale (mRS) Scores
Proportion of Participants With a National Institutes of Health Stroke Scale (NIHSS) Score of 0-1
Proportion of Participants With an Increase From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
Proportion of Participants With a Decrease From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
Show 11 moreShow less
Proportion of Participants With a COSMOS score Grade of 0-1
COSMOS Score
Health-Related Quality of Life Assessed by EQ-5D-3L and EQ VAS
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 36 Hours
Incidence of Any Intracranial Hemorrhage Within 36 Hours
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 7 Days
Incidence of Major Extracranial Bleeding According to ISTH Criteria
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 5-6
All-Cause Mortality
Proportion of Participants Experiencing at Least One Adverse Event
Proportion of Participants Experiencing at Least One Serious Adverse Event

Arms and interventions

Low-Dose Tenecteplase (rhTNK-tPA)Experimental

Participants will receive rhTNK-tPA at 0.18 mg/kg, with a maximum dose of 16 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

Standard-Dose Tenecteplase (rhTNK-tPA)Active comparator

Participants will receive rhTNK-tPA at 0.25 mg/kg, with a maximum dose of 25 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

Drugs: Tenecteplase 0.18 mg/kg, Tenecteplase 0.25 mg/kg

Sites

1 site in 1 country

  • Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinan, Shandong, China